跳至主要内容
临床试验/NCT04339725
NCT04339725进行中(未招募)不适用

Research Based on Gut Microbiota Metagenomics for Prevention of Chronic Liver Disease

Chuncheon Sacred Heart Hospital1 个研究点 分布在 1 个国家目标入组 3,240 人开始时间: 2017年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
3,240
试验地点
1
主要终点
Fecal DNA

研究概览

简要总结

Gut microbiota modulation has effect on chronic liver disease

详细描述

Chronic liver disease has been known as a disease of the liver which lasts over a period of 6-month. It consists of inflammation, hepatitis, cirrhosis, hepatocellular carcinoma.

Gut microbiota plays an important roles in the chronic liver disease. It can suppress the progression of the liver disease by moulation gut microbiota.

The investigators are still evaluating the effect of gut microbiota on the liver disease.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
31 Years 至 82 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Normal : AST or ALT level < 50IU/L, BMI < 25
  • Liver disease : AST or ATL level ≥ 50IU/L, BMI ≥ 25
  • Patients hospitalized with chronic liver disease (viral hepatitis, alcoholic liver disease, non-alcoholic liver disease, cirrhosis, liver cancer)

排除标准

  • Normal : AST or ATL level ≥ 50IU/L, BMI ≥ 25
  • Liver disease : AST or ALT level < 50IU/L, BMI < 25
  • If the patient refuses

结局指标

主要结局

Fecal DNA

时间窗: 10 years

Compare the species and proportions of the gut microbiome

BMI

时间窗: 10 years

Compare the body mass index

Liver enzyme

时间窗: 10 years

Compare the liver enzyme level

次要结局

未报告次要终点

研究者

发起方
Chuncheon Sacred Heart Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ki Tae Suk

Proffesor

Chuncheon Sacred Heart Hospital

研究点 (1)

Loading locations...

相似试验

Gut Microbiota Metagenomics for Chronic Liver Disease | 临床试验